Decoy Therapeutics Inc. (DCOY)
NASDAQ: DCOY · Real-Time Price · USD
8.61
+0.25 (2.99%)
At close: Jun 2, 2026, 4:00 PM EDT
8.50
-0.11 (-1.28%)
Pre-market: Jun 3, 2026, 7:38 AM EDT
Decoy Therapeutics Employees
Decoy Therapeutics had 11 employees as of December 31, 2025. The number of employees increased by 9 or 450.00% compared to the previous year.
Employees
11
Change (1Y)
9
Growth (1Y)
450.00%
Revenue / Employee
n/a
Profits / Employee
-$1,184,870
Market Cap
4.58M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 11 | 9 | 450.00% | 11 | 0 |
| Dec 31, 2024 | 2 | 0 | - | 2 | 0 |
| Dec 31, 2023 | 2 | -10 | -83.33% | 2 | 0 |
| Dec 31, 2022 | 12 | -4 | -25.00% | 12 | 0 |
| Dec 31, 2021 | 16 | 7 | 77.78% | 16 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| VivoSim Labs | 14 |
| Azitra | 13 |
| TransCode Therapeutics | 12 |
| Revelation Biosciences | 9 |
| Dermata Therapeutics | 9 |
| Alzamend Neuro | 6 |
| Galmed Pharmaceuticals | 6 |
| CDT Equity | 4 |
DCOY News
- 1 hour ago - Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors - PRNewsWire
- 2 days ago - Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic - PRNewsWire
- 8 days ago - Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board - PRNewsWire
- 26 days ago - Decoy Therapeutics Quarterly report: Q1 2026 - Filings
- 5 weeks ago - Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston - PRNewsWire
- 7 weeks ago - Decoy Therapeutics Transcript: Status update - Transcripts
- 7 weeks ago - Decoy Therapeutics Press release: Status update - Filings
- 7 weeks ago - Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline - PRNewsWire